dc.contributor.author |
Billioux, Veena G. |
|
dc.contributor.author |
Chang, Larry W. |
|
dc.contributor.author |
Reynolds, Steven J. |
|
dc.contributor.author |
Nakigozi, Gertrude |
|
dc.contributor.author |
Ssekasanvu, Joseph |
|
dc.contributor.author |
Grabowski, Mary K. |
|
dc.contributor.author |
Ssekubugu, Robert |
|
dc.contributor.author |
Nalugoda, Fred |
|
dc.contributor.author |
Kigozi, Godfrey |
|
dc.contributor.author |
Kagaayi, Joseph |
|
dc.contributor.author |
Serwadda, David |
|
dc.contributor.author |
Gray, Ronald H. |
|
dc.contributor.author |
Wawer, Maria J. |
|
dc.date.accessioned |
2021-01-01T21:58:22Z |
|
dc.date.available |
2021-01-01T21:58:22Z |
|
dc.date.issued |
2017 |
|
dc.identifier.uri |
http://combine.alvar.ug/handle/1/48281 |
|
dc.description.abstract |
Introduction: To assess progress towards the UNAIDS 90-90-90 initiative targets, we examined the HIV care cascade in the population-based Rakai Community Cohort Study (RCCS) in rural Uganda and examined differences between sub-groups. Methods: Self-reports and clinical records were used to assess the proportion achieving each stage in the cascade. Statistical inference based on a chi(2) test for categorical variables and modified Poisson regression were used to estimate prevalence risk ratios (PRRs) and 95% confidence intervals (CI) for enrolment into care and initiating antiretroviral therapy (ART). Results: From September 2013 through December 2015, 3,666 HIV-positive participants were identified in the RCCS. As of December 2015, 98% had received HIV Counseling and Testing (HCT), 74% were enrolled in HIV care, and 63% had initiated ART of whom 92% were virally suppressed after 12 months on ART. Engagement in care was lower among men than women (enrolment in care: adjPRR 0.84, 95% CI 0.77-0.91; ART initiation: adjPRR 0.75, 95% CI 0.69-0.82), persons aged 15-24 compared to those aged 30-39 (enrolment: adjPRR 0.72, 95% CI 0.63-0.82; ART: adjPRR 0.69, 95% CI 0.60-0.80), unmarried persons (enrolment: adjPRR 0.84, 95% CI 0.71-0.99; ART adjPRR 0.80, 95% CI 0.66-0.95), and new in-migrants (enrolment: adjPRR 0.75, 95% CI 0.67-0.83; ART: adjPRR 0.76, 95% CI 0.67-0.85). This cohort achieved 98-65-92 towards the UNAIDS "90-90-90" targets with an estimated 58% of the entire HIV-positive RCCS population virally suppressed. Conclusions: This cohort achieved over 90% in both HCT and viral suppression among ART users, but only 65% in initiating ART, likely due to both an ART eligibility criterion of <500 CD4 cells/mL and suboptimal entry into care among men, younger individuals, and in-migrants. Interventions are needed to promote enrolment in HIV care, particular for hard-to-reach subpopulations. |
|
dc.description.sponsorship |
National Institute of Allergy and Infectious DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [RO1AI114438, RO1AI110324, UO1AI10031] |
|
dc.description.sponsorship |
Division of Intramural ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA |
|
dc.description.sponsorship |
National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [RO1MH107275] |
|
dc.description.sponsorship |
National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1HD070769] |
|
dc.description.sponsorship |
Bill & Melinda Gates FoundationBill & Melinda Gates Foundation [22006.03] |
|
dc.description.sponsorship |
World BankThe World Bank India [7166975] |
|
dc.description.sponsorship |
Centers for Disease control and Protection [USGPS000971] |
|
dc.description.sponsorship |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, K01AI125086, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, R01AI110324, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, K01AI125086, P30AI094189, ZIAAI001040, P30AI094189, R01AI114438, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, ZIAAI001040, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, K01AI125086, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189, K01AI125086, P30AI094189, P30AI094189, P30AI094189, P30AI094189, P30AI094189] Funding Source: NIH RePORTER |
|
dc.description.sponsorship |
NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH107275, R01MH107275, R01MH107275, R01MH107275, R01MH107275] Funding Source: NIH RePORTER |
|
dc.language |
English |
|
dc.publisher |
JOHN WILEY & SONS LTD |
|
dc.relation.ispartof |
Journal of the International AIDS Society |
|
dc.subject |
Hiv |
|
dc.subject |
Antiretroviral |
|
dc.subject |
Hiv Care Cascade |
|
dc.subject |
Rakai |
|
dc.subject |
Uganda |
|
dc.title |
Human immunodeficiency virus care cascade among sub-populations in Rakai, Uganda: an observational study |
|
dc.type |
Article |
|
dc.identifier.isi |
000402641500001 |
|
dc.identifier.doi |
10.7448/IAS.20.1.21590 |
|
dc.identifier.pmid |
285171 |
|
dc.publisher.city |
CHICHESTER |
|
dc.publisher.address |
THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND |
|
dc.identifier.eissn |
1758-2652 |
|
dc.identifier.volume |
20 |
|
dc.subject.wc |
Immunology |
|
dc.subject.wc |
Infectious Diseases |
|
dc.subject.sc |
Immunology |
|
dc.subject.sc |
Infectious Diseases |
|
dc.description.oa |
DOAJ Gold |
|
dc.description.oa |
Green Published |
|
dc.description.pages |
9 |
|
dc.contributor.group |
Rakai Hlth Sci Program |
|
dc.subject.kwp |
Hiv-Infected Patients |
|
dc.subject.kwp |
Antiretroviral Therapy |
|
dc.subject.kwp |
Early Retention |
|
dc.subject.kwp |
Viral Load |
|
dc.subject.kwp |
Transmission |
|
dc.subject.kwp |
Plasma |
|
dc.subject.kwp |
Seroconversion |
|
dc.subject.kwp |
Probability |
|
dc.subject.kwp |
Engagement |
|
dc.subject.kwp |
Prevention |
|
dc.identifier.articleno |
21590 |
|
dc.description.affiliation |
Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 627 North Washington St, Baltimore, MD 21205 USA |
|
dc.description.affiliation |
Rakai Hlth Sci Program, Dept Rakai Community Cohort Study, Kalisizo, Uganda |
|
dc.description.affiliation |
Johns Hopkins Sch Med, Dept Med, Div Infect Dis, Baltimore, MD USA |
|
dc.description.affiliation |
NIAID, Immunoregulat Lab, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA |
|
dc.description.affiliation |
Makerere Univ, Dept Dis Control & Environm Hlth, Sch Publ Hlth, Kampala, Uganda |
|
dc.description.email |
vgoud1@jhu.edu |
|
dc.description.corr |
Billioux, VG (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 627 North Washington St, Baltimore, MD 21205 USA. |
|
dc.description.orcid |
Reynolds, Steven/0000-0002-5403-2759 |
|